
First Tracks Biotherapeutics Inc
TRAXHealthcare|Biotechnology|US
$47.90
+2.47 (+5.44%)
DCF Value
$6.37
Tangible Book / Share
$4.22
Cash / Share
$4.35
Ownership Breakdown
85.3%
Float
42.0M
Shares Outstanding
35.9M
Float Shares
Major Holders (15)
Combined: 114.6%
Holders of 5%+ from their latest Schedule 13D/13G filing in the last two years. Percentages are as of each filing date.
| Holder | Type | % of Class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| FMR LLC | Holding company | 15.00% | 6,302,672 | Nov 6, 2026 | 13D/G |
| Abigail P. Johnson | Individual | 15.00% | 6,302,672 | Nov 6, 2026 | 13D/G |
| Oleg Nodelman | HC, IN | 9.10% | 3,174,519 | Apr 22, 2026 | 13D/G |
| EcoR1 Capital, LLC | IA, OO | 9.10% | 3,174,519 | Apr 22, 2026 | 13D/G |
| EcoR1 Capital Fund Qualified, L.P. | Partnership | 8.50% | 2,981,908 | Apr 22, 2026 | 13D/G |
| Chen Yu | Individual | 8.30% | 2,895,304 | Aug 14, 2026 | 13D/G |
| BlackRock, Inc. | Holding company | 7.20% | 2,558,473 | Oct 27, 2026 | 13D/G |
| Sirenia Capital Management LP | IA, PN | 7.20% | 2,495,777 | Aug 14, 2026 | 13D/G |
| Alex Silverstein | HC, IN | 7.20% | 2,495,777 | Aug 14, 2026 | 13D/G |
| Affinity Asset Advisors, LLC | IA, OO | 5.80% | 2,032,012 | Aug 13, 2026 | 13D/G |
| Michael Cho | HC, IN | 5.80% | 2,032,012 | Aug 13, 2026 | 13D/G |
| TCG Crossover Fund II, L.P. | Partnership | 4.10% | 1,447,652 | Aug 14, 2026 | 13D/G |
| TCG Crossover GP III, LLC | Other | 4.10% | 1,447,652 | Aug 14, 2026 | 13D/G |
| TCG Crossover Fund III, L.P. | Partnership | 4.10% | 1,447,652 | Aug 14, 2026 | 13D/G |
| TCG Crossover GP II, LLC | Other | 4.10% | 1,447,652 | Aug 14, 2026 | 13D/G |
Insider Trades (21)
Last 4 quarters: 933,184 acquired · 79,930 disposed
| Insider | Position | Date | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Tamboli Ajim | Chief Financial Officer | Nov 1, 2026 | AWARD | 42,500 | — | — | Form 4 |
| Faga Daniel | director, officer: President, CEO | Nov 1, 2026 | AWARD | 136,000 | — | — | Form 4 |
| STONE BENJAMIN | Chief Business Officer | Nov 1, 2026 | AWARD | 42,500 | — | — | Form 4 |
| Lizzul Paul F. | Chief Medical Officer | Nov 1, 2026 | AWARD | 42,500 | — | — | Form 4 |
| Orwin John A | director | Sep 15, 2026 | OPTION EX. | 1,300 | — | — | Form 4 |
| Orwin John A | director | Sep 15, 2026 | OPTION EX. | 1,300 | — | — | Form 4 |
| Ware J. Anthony | director | Sep 2, 2026 | OPTION EX. | 39,265 | $5.74 | $225.4K | Form 4 |
| Ware J. Anthony | director | Sep 2, 2026 | SELL | 39,265 | $44.78 | $1.8M | Form 4 |
| Ware J. Anthony | director | Sep 2, 2026 | OPTION EX. | 28,571 | $5.74 | $164.0K | Form 4 |
| Ware J. Anthony | director | Sep 2, 2026 | OPTION EX. | 10,694 | $5.74 | $61.4K | Form 4 |
| STONE BENJAMIN | Chief Business Officer | Aug 15, 2026 | AWARD | 60,492 | — | — | Form 4 |
| Lizzul Paul F. | Chief Medical Officer | Aug 15, 2026 | AWARD | 60,492 | — | — | Form 4 |
| Faga Daniel | director, officer: President, CEO | Aug 15, 2026 | AWARD | 193,575 | — | — | Form 4 |
| Lizzul Paul F. | Chief Medical Officer | Apr 20, 2026 | OTHER | 16,667 | — | — | Form 4 |
| STONE BENJAMIN | Chief Business Officer | Apr 20, 2026 | OTHER | 16,667 | — | — | Form 4 |
| Faga Daniel | director, officer: President, CEO | Apr 20, 2026 | OTHER | 53,334 | — | — | Form 4 |
| STONE BENJAMIN | Chief Business Officer | Aug 2, 2026 | AWARD | 60,492 | — | — | Form 4 |
| Lizzul Paul F. | Chief Medical Officer | Aug 2, 2026 | AWARD | 60,492 | — | — | Form 4 |
| Faga Daniel | director, officer: President, CEO | Aug 2, 2026 | AWARD | 193,576 | — | — | Form 4 |
| ANAPTYSBIO, INC | 10 percent owner | Apr 20, 2026 | DISPOSED | 100 | — | — | Form 4 |
| ANAPTYSBIO, INC | 10 percent owner | Apr 1, 2026 | OTHER | 0 | — | — | Form 4 |